MDT Medtronic

XNYS Up Alert

Health Care

· How we analyze

About the company

Medtronic is a medical technology company based in Ireland. It makes pacemakers, heart valves, insulin pumps, spinal implants, neurostimulators and surgical instruments. The diabetes division is to be separated. As of Oct 13, 2026

Fact sheet (from the annual report) Electromedical equipment · Galway

Medtronic, based in Galway, Ireland, serves health systems, physicians, clinicians and patients. The Cardiovascular Portfolio, Neuroscience Portfolio and Medical Surgical Portfolio segments develop, manufacture and sell mainly device-based therapies and services. In cardiology, the offering includes pacemakers, products for atrial fibrillation and products for heart valve repair and replacement. Neuroscience comprises navigation and robotic systems for spine and cranial procedures, spinal implants and stroke products. The Medical Surgical Portfolio is aimed mainly at health systems, physician offices and ambulatory surgery centers. In March 2026 the MiniMed diabetes division completed an initial public offering, and in the final quarter of fiscal year 2026 diabetes was no longer a reportable segment.

Automatically summarized from SEC annual report (10-K, filed Jun 18, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

Price performance at a glance

Last 30 trading days
  • Today −0.9%
  • 7 days −0.7%
  • 30 days +6.0%
  • 1 year −0.2%
Day range (last trading day)
−0.2%Price at 25% of the range+0.6%
52-week range
−22.0%Price at 63% of the range+13.2%
Distance from the all-time high
−30.9%

Our own calculation from the exchange’s daily candles, as of Oct 27, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Fundamentals · Analysis method

Growth, margin and debt compared with the sector – in detail in the fundamental analysis further down. The chart shows the candles without a buy zone.

Growth: yellowMargin: greenDebt: gray

Load chart from TradingView

This transfers data (including your IP address) to TradingView, also to the USA. More in the Privacy policy.

Symbol on TradingView: NYSE:MDT

Fundamental analysis

Medtronic · Sector Health Care · amounts in USD

Information only – does not affect our buy zones, not investment advice. Source: SEC filings, As of Jun 18, 2026.

In short

  • Light yellow: Revenue grew over 5 years (+3.8% per year), more slowly than the sector median.
  • Light yellow: Net income (total) grew over 5 years (+5.9% per year), more slowly than the sector median; per share +7.0% per year.
  • Light green: Net margin 13.2%, above the sector median (12.9%).
  • Light green: Profit in each of the last 10 fiscal years.
  • Light yellow: High payout ratio (76% of earnings).

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2017 (Apr 30, 2016 – Apr 28, 2017): Revenue 29.7B USD · Net income 4.0B USD · Net margin 13.6%
  2. Fiscal year 2018 (Apr 29, 2017 – Apr 27, 2018): Revenue 30.0B USD · Net income 3.1B USD · Net margin 10.4%
  3. Fiscal year 2019 (Apr 28, 2018 – Apr 26, 2019): Revenue 30.6B USD · Net income 4.6B USD · Net margin 15.2%
  4. Fiscal year 2020 (Apr 27, 2019 – Apr 24, 2020): Revenue 28.9B USD · Net income 4.8B USD · Net margin 16.6%
  5. Fiscal year 2021 (Apr 25, 2020 – Apr 30, 2021): Revenue 30.1B USD · Net income 3.6B USD · Net margin 12.0%
  6. Fiscal year 2022 (May 1, 2021 – Apr 29, 2022): Revenue 31.7B USD · Net income 5.0B USD · Net margin 15.9%
  7. Fiscal year 2023 (Apr 30, 2022 – Apr 28, 2023): Revenue 31.2B USD · Net income 3.8B USD · Net margin 12.0%
  8. Fiscal year 2024 (Apr 29, 2023 – Apr 26, 2024): Revenue 32.4B USD · Net income 3.7B USD · Net margin 11.4%
  9. Fiscal year 2025 (Apr 27, 2024 – Apr 25, 2025): Revenue 33.5B USD · Net income 4.7B USD · Net margin 13.9%
  10. Fiscal year 2026 (Apr 26, 2025 – Apr 24, 2026): Revenue 36.4B USD · Net income 4.8B USD · Net margin 13.2%

Fiscal year 2026 (Apr 26, 2025 – Apr 24, 2026): Revenue 36.4B USD · Net income 4.8B USD · Net margin 13.2%

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light yellow: below sector

+3.8% per year, last 5 years

Sector Health Care: median +7.8% (60 symbols)

What does this mean? Revenue: over 5 years it grew by 3.8% per year on average, but more slowly than the median company in the sector (+7.8%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light yellow: below sector

+5.9% per year, last 5 years

Sector Health Care: median +7.5% (46 symbols)

per share: +7.0% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it grew by 5.9% per year on average, but more slowly than the median company in the sector (+7.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light green: above sector

13.2% last fiscal year

Sector Health Care: median 12.9% (63 symbols)

What does this mean? Of every 100 USD in revenue, 13.20 USD remained as profit – at least as much as the median company in the sector (12.9%). Five years ago the margin was 12.0%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light gray: not available

– latest balance sheet

Sector Health Care: median 0.66 (40 symbols)

What does this mean? No usable figure: reported financial debt or positive equity for the same balance sheet date is missing.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light yellow: high

76% Dividend / earnings per share

Sector Health Care: median 28% (31 symbols)

What does this mean? Of every 1 USD of earnings per share, 0.76 USD went to shareholders as a dividend. Little buffer remains for weaker years. Median company in the sector: 28%.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
36.4B USD
Revenue vs. prior year
+8.4%
Net income (FY)
4.8B USD
Net income vs. prior year
+3.0%
EPS (FY)
3.73 USD
13F funds with a position
1 of 9
Funds vs. prior quarter
±0
Shares held vs. prior quarter
+1,330.3%
Fiscal year to Apr 24, 2026 · 10-K filed Jun 18, 2026 · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). 13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2026Apr 24, 2026 36.4B4.8B 13.2% 3.73 2.84 76%
2025Apr 25, 2025 33.5B4.7B 13.9% 3.61 2.80 78%
2024Apr 26, 2024 32.4B3.7B 11.4% 2.76 2.76 100%
2023Apr 28, 2023 31.2B3.8B 12.0% 2.82 2.72 96%
2022Apr 29, 2022 31.7B5.0B 15.9% 3.73 2.52 68%
2021Apr 30, 2021 30.1B3.6B 12.0% 2.66 2.32 87%
2020Apr 24, 2020 28.9B4.8B 16.6% 3.54 2.16 61%
2019Apr 26, 2019 30.6B4.6B 15.2% 3.41 2.00 59%
2018Apr 27, 2018 30.0B3.1B 10.4% 2.27 1.84 81%
2017Apr 28, 2017 29.7B4.0B 13.6% 2.89 1.72 60%
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q3/26Jul 31, 2026 9.8B1.5B 15.1% 1.14 0.72 63%
Q2/26*Apr 24, 2026 9.8B1.2B 12.7% – – –
Q1/26Jan 23, 2026 9.0B1.1B 12.7% 0.89 0.71 80%
Q4/25Oct 24, 2025 9.0B1.4B 15.3% 1.07 0.71 66%
Q3/25Jul 25, 2025 8.6B1.0B 12.1% 0.81 0.71 88%
Q2/25*Apr 25, 2025 8.9B1.1B 11.8% – – –
Q1/25Jan 24, 2025 8.3B1.3B 15.6% 1.01 0.70 69%
Q4/24Oct 25, 2024 8.4B1.3B 15.1% 0.99 0.70 71%
Q3/24Jul 26, 2024 7.9B1.0B 13.2% 0.80 0.70 88%
Q2/24*Apr 26, 2024 8.6B654.0M 7.6% – – –
Q1/24Jan 26, 2024 8.1B1.3B 16.3% 0.99 0.69 70%
Q4/23Oct 27, 2023 8.0B909.0M 11.4% 0.68 0.69 101%

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $5.9M3 people −$5.9M
6 months $00 people $6.5M4 people −$6.5M
12 months $00 people $14.7M5 people −$14.7M

Latest transactions

  • Oct 15, 2026 Marinaro Michael Officer Open-market sale · 10b5-1 plan 10,420 shares · $1.0M · SEC
  • Oct 15, 2026 Martha Geoffrey Chief executive (CEO), Director Open-market sale · 10b5-1 plan 50,000 shares · $4.8M · SEC
  • Sep 16, 2026 Kiil Harry Skip Officer Open-market sale 1,483 shares · $138.9K · SEC
  • Jul 8, 2026 Walter Matthew R. Officer Open-market sale · 10b5-1 plan 3,102 shares · $257.9K · SEC
  • Jun 8, 2026 Kiil Harry Skip Officer Open-market sale 228 shares · $18.3K · SEC
  • Jun 8, 2026 Kiil Harry Skip Officer Open-market sale 3,961 shares · $318.6K · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Trend score +65

Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+0
Highs and lows+0
Relative strength+15

Volatility and trend strength

ADX 14 (trend strength)20.8
Rel. strength 60 d+7.3%

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on MDT yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: MDT

Alerts with a free account: we send you an email as soon as the price moves above or below your level, reaches the buy zone or the buy zone becomes invalid.

Checked after every data update: crypto hourly (buy zones every 4 hours), stocks twice a day, precious metals every 4 hours on trading days, extended universe weekly – not in real time.

Log in Sign up free

↑ ↓ select · Enter open · Esc close